Sawai Eyes Global Position Helped by Japan Growth And Upsher-Smith – But No Biosimilars

In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.